Breast cancer vaccines: maximizing peptide-based vaccines by regulatory T cell depletion and toll-like receptor 9 activation

Nava‐Parada, Pilar; Herron, Adam; Knutson, Keith L.; Pease, Larry R.; Celis, Esteban

doi:10.1186/1471-2407-7-s1-a2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Specific Strategies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-CD-25 monoclonal antibody has been shown to deplete Tregs, and this may increase the effectiveness of a subsequent peptide-based vaccine. Support for this idea comes from a recent study by Nava-Parada et al 38 These researchers used neu-T mice that show targeted expression of rat neu in breast tissue at 3 to 4 weeks of age and develop spontaneous breast tumors at 15 to 17 weeks. Vaccination of neu-T mice with an anti-neu vaccine prevented both spontaneous and transplanted tumors, but only when given with repeated boosters.…”

Section: Specific Strategiesmentioning

confidence: 99%

Breast cancer vaccines

Mittendorf

Peoples

Singletary

2007

Cancer

View full text Add to dashboard Cite

show abstract

Section: Specific Strategiesmentioning

confidence: 99%

Breast cancer vaccines

Mittendorf

Peoples

Singletary

2007

Cancer

View full text Add to dashboard Cite

show abstract

The Therapeutic Potential of Targeting the Toll-like Receptor Pathway in Breast Cancer

Toroghian

Khayyami

Hassanian

et al. 2022

CPD

View full text Add to dashboard Cite

The toll-like receptor (TLR) signaling pathway plays a key role in inducing immune responses and were shown to be expressed in immune cells and tumor cells, and is involved in the progression of several malignancies including breast cancer. These findings provide a proof of the concept of targeting this pathway as a potential therapeutic option in the treatment of breast cancer. Moreover, there is a growing body of data showing the activation of TLRs in the tumor microenvironment and its dual function as anti-tumoral (dendritic T and natural killer cells activation) or pro-tumoral activity (cell proliferation, and drug resistance). Several agents have been developed for targeting of this pathway and one of these inhibitors, called Bacillus Calmette-Guerin (an agonist of TLR2 and TLR4), is recently being approved by FDA for immunotherapy of bladder cancer. This review summarizes the current knowledge of the mechanisms of action of TLR pathways in the development/progression of cancer for a better management of this disease.

show abstract

Breast cancer vaccines: maximizing peptide-based vaccines by regulatory T cell depletion and toll-like receptor 9 activation

Cited by 2 publications

References 0 publications

Breast cancer vaccines

Breast cancer vaccines

The Therapeutic Potential of Targeting the Toll-like Receptor Pathway in Breast Cancer

Contact Info

Product

Resources

About